On the public citation graph
A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
0 signed · 1229 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/1531-8249(199908)46:2<197::aid-ana9>3.0.co;2-popenalex-snapshot
Magnetic resonance imaging results of the PRISMS trial: A randomized, double-blind, placebo-controlled study of interferon-?1a in relapsing-remitting multiple sclerosis
inferredcites →https://doi.org/10.1002/1531-8249(199909)46:3<296::aid-ana4>3.0.co;2-#openalex-snapshot
Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis
inferredcites →https://doi.org/10.1002/ana.410130302openalex-snapshot
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
inferredcites →https://doi.org/10.1002/ana.410290111openalex-snapshot
Major differences in the dynamics of primary and secondary progressive multiple sclerosis
inferredcites →https://doi.org/10.1002/ana.410290515openalex-snapshot
Serial gadolinium‐enhanced magnetic resonance imaging scans in patients with early, relapsing‐remitting multiple sclerosis: Implications for clinical trials and natural history
inferredcites →https://doi.org/10.1002/ana.410390304openalex-snapshot
Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis
inferredcites →https://doi.org/10.1002/ana.64openalex-snapshot
European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis
inferredcites →https://doi.org/10.1002/jmri.1880050510openalex-snapshot
A monoclonal antibody to α4‐integrin reverses the MR‐detectable signs of experimental allergic encephalomyelitis in the Guinea pig
inferredcites →https://doi.org/10.1016/0092-8674(87)90233-9openalex-snapshot
Integrins: A family of cell surface receptors
inferredcites →https://doi.org/10.1016/0165-5728(94)00165-kopenalex-snapshot
A monoclonal antibody to α4 integrin suppresses and reverses active experimental allergic encephalomyelitis
inferredcites →https://doi.org/10.1016/0730-725x(96)00018-5openalex-snapshot
Quantification of MRI lesion load in multiple sclerosis: A comparison of three computer-assisted techniques
inferredcites →https://doi.org/10.1016/s0140-6736(98)03334-0openalex-snapshot
Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis
inferredcites →https://doi.org/10.1038/356063a0openalex-snapshot
Prevention of experimental autoimmune encephalomyelitis by antibodies against α4βl integrin
inferredcites →https://doi.org/10.1056/nejm199607043350108openalex-snapshot
Adhesion Molecules — Blood Vessels and Blood Cells
inferredcites →https://doi.org/10.1056/nejmoa020732openalex-snapshot
Natalizumab for Active Crohn's Disease
inferredcites →https://doi.org/10.1136/jnnp.52.10.1216-aopenalex-snapshot
A Colour Atlas of Multiple Sclerosis and Other Myelin Disorders
inferredcites →https://doi.org/10.1212/wnl.33.11.1444openalex-snapshot
Rating neurologic impairment in multiple sclerosis
inferredcites →https://doi.org/10.1212/wnl.42.1.60openalex-snapshot
Serial gadolinium‐enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration
inferredcites →https://doi.org/10.1212/wnl.45.7.1268openalex-snapshot
Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis
inferredcites →https://doi.org/10.1212/wnl.45.7.1277openalex-snapshot
Interferon beta‐lb in the treatment of multiple sclerosis
inferredcites →https://doi.org/10.1212/wnl.46.4.907openalex-snapshot
Defining the clinical course of multiple sclerosis
inferredcites →https://doi.org/10.1212/wnl.53.3.466openalex-snapshot
The effect of anti-α4 integrin antibody on brain lesion activity in MS
inferredcites →https://doi.org/10.2307/2289477openalex-snapshot
Sample Size Determination for Some Common Nonparametric Tests
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.1001/archneur.61.10.1610openalex-snapshot
Multiple Sclerosis Is Not an Autoimmune Disease
inferred← citeshttps://doi.org/10.1001/archneur.61.10.1613openalex-snapshot
Multiple Sclerosis Is an Inflammatory T-Cell–Mediated Autoimmune Disease
inferred← citeshttps://doi.org/10.1001/archneur.62.4.688-aopenalex-snapshot
Evaluating the Evidence for Multiple Sclerosis as an Autoimmune Disease
inferred← citeshttps://doi.org/10.1001/archneur.62.6.858openalex-snapshot
Glatiramer Acetate Therapy: The Plot Thickens
inferred← citeshttps://doi.org/10.1001/archneur.62.9.1345openalex-snapshot
Characterizing the Mechanisms of Progression in Multiple Sclerosis
inferred← citeshttps://doi.org/10.1001/archneur.63.10.1383openalex-snapshot
Altered CD4+/CD8+ T-Cell Ratios in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis
inferred← citeshttps://doi.org/10.1001/archneur.64.2.169openalex-snapshot
Potential Risk of Progressive Multifocal Leukoencephalopathy With Natalizumab Therapy
inferred← citeshttps://doi.org/10.1001/archneur.64.9.1331openalex-snapshot
Delayed Allergic Reaction to Natalizumab Associated With Early Formation of Neutralizing Antibodies
inferred← citeshttps://doi.org/10.1001/archneur.65.12.1655openalex-snapshot
Natalizumab Use in Pediatric Multiple Sclerosis
inferred← citeshttps://doi.org/10.1001/archneur.65.12.noc80051openalex-snapshot
Decrease in the Numbers of Dendritic Cells and CD4+ T Cells in Cerebral Perivascular Spaces Due to Natalizumab
inferred← citeshttps://doi.org/10.1001/archneur.65.5.656openalex-snapshot
Allergic and Nonallergic Delayed Infusion Reactions During Natalizumab Therapy
inferred← citeshttps://doi.org/10.1001/archneurol.2007.33openalex-snapshot
Specificity and Correlation With Disease Activity of Cerebrospinal Fluid Osteopontin Levels in Patients With Multiple Sclerosis
inferred← citeshttps://doi.org/10.1001/archneurol.2010.143openalex-snapshot
Natalizumab Treatment in a Patient With Chronic Inflammatory Demyelinating Polyneuropathy
inferred← citeshttps://doi.org/10.1001/archneurol.2010.161openalex-snapshot
Natalizumab and Progressive Multifocal Leukoencephalopathy
inferred← citeshttps://doi.org/10.1001/archneurol.2010.247openalex-snapshot
Translational Research in Neurology and Neuroscience 2010-2011
inferred← citeshttps://doi.org/10.1001/archneurol.2010.257openalex-snapshot
Immune Reconstitution Inflammatory Syndrome in Patients With Multiple Sclerosis Following Cessation of Natalizumab Therapy
inferred← citeshttps://doi.org/10.1001/jama.296.7.815openalex-snapshot
Biology of CCR5 and Its Role in HIV Infection and Treatment
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2021.44750openalex-snapshot
Multiple Sclerosis Disease Activity and Disability Following Discontinuation of Natalizumab for Pregnancy
inferred← citeshttps://doi.org/10.1001/jamaneurol.2022.5007openalex-snapshot
Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis
inferred← citeshttps://doi.org/10.1001/jamaneurol.2023.1542openalex-snapshot
Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation
inferred← citeshttps://doi.org/10.1002/14651858.cd003057.pub2openalex-snapshot
Hyperbaric oxygen therapy for multiple sclerosis
inferred← citeshttps://doi.org/10.1002/14651858.cd006097openalex-snapshot
Natalizumab for induction of remission in Crohn's disease
inferred← citeshttps://doi.org/10.1002/14651858.cd006097.pub2openalex-snapshot
Natalizumab for induction of remission in Crohn's disease
inferred← citeshttps://doi.org/10.1002/14651858.cd007621openalex-snapshot
Natalizumab for relapsing remitting multiple sclerosis
inferred← citeshttps://doi.org/10.1002/14651858.cd007621.pub2openalex-snapshot
Natalizumab for relapsing remitting multiple sclerosis
inferred← citeshttps://doi.org/10.1002/14651858.cd012186.pub2openalex-snapshot
Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis
inferred← citeshttps://doi.org/10.1002/3527608141.ch7bopenalex-snapshot
Kv1.3 Potassium Channel: Physiology, Pharmacology and Therapeutic Indications
inferred← citeshttps://doi.org/10.1002/9780470101001.hcn066openalex-snapshot
Pharmacology of Inflammation
inferred← citeshttps://doi.org/10.1002/9780470101001.hcn067openalex-snapshot
Pharmacological Treatment of Multiple Sclerosis
inferred← citeshttps://doi.org/10.1002/9780470101001.hcn068openalex-snapshot
Novel Therapies for Multiple Sclerosis
inferred← citeshttps://doi.org/10.1002/9780470571224.pse437openalex-snapshot
Gold Standard Animal Models
inferred← citeshttps://doi.org/10.1002/9780470692363.ch1openalex-snapshot
The Basics of Cellular and Molecular Immunology
inferred← citeshttps://doi.org/10.1002/9780470753279.ch6openalex-snapshot
Use of Imaging in Multiple Sclerosis
inferred← citeshttps://doi.org/10.1002/9781118314814.ch6openalex-snapshot
Neural Functions of Hematopoietic‐derived Cells
inferred← citeshttps://doi.org/10.1002/9781118732748.ch4openalex-snapshot
Microglia and Macrophage Responses and Their Role after Spinal Cord Injury
inferred← citeshttps://doi.org/10.1002/9781118940648.ch3openalex-snapshot
Mechanism of Action for Therapeutic Antibodies
inferred← citeshttps://doi.org/10.1002/9781119963714.ch8openalex-snapshot
Medication Treatment in Multiple Sclerosis
inferred← citeshttps://doi.org/10.1002/9781444328394.ch3openalex-snapshot
Use of Imaging in Multiple Sclerosis
inferred← citeshttps://doi.org/10.1002/9783527619740.ch26openalex-snapshot
Antibodies in Phase I/II/III: Targeting TNF
inferred← citeshttps://doi.org/10.1002/acn3.51510openalex-snapshot
Sustained immunotolerance in multiple sclerosis after stem cell transplant
inferred← citeshttps://doi.org/10.1002/acn3.664openalex-snapshot
TLR 3 agonism re‐establishes CNS immune competence during α4‐integrin deficiency
inferred← citeshttps://doi.org/10.1002/acn3.84openalex-snapshot
Immunomodulatory activity of interferon‐beta
inferred← citeshttps://doi.org/10.1002/adbi.202300073openalex-snapshot
Dendritic Cells as a Nexus for the Development of Multiple Sclerosis and Models of Disease
inferred← citeshttps://doi.org/10.1002/ana.20832openalex-snapshot
Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: Have we been overly harsh in our assessment?
inferred← citeshttps://doi.org/10.1002/ana.20858openalex-snapshot
Immune surveillance in multiple sclerosis patients treated with natalizumab
inferred← citeshttps://doi.org/10.1002/ana.20859openalex-snapshot
Natalizumab effects on immune cell responses in multiple sclerosis
inferred← citeshttps://doi.org/10.1002/ana.20877openalex-snapshot
Natalizumab: Immune effects and implications for therapy
inferred← citeshttps://doi.org/10.1002/ana.20933openalex-snapshot
Progressive multifocal leukoencephalopathy revisited: Has the disease outgrown its name?
inferred← citeshttps://doi.org/10.1002/ana.21163openalex-snapshot
Health‐related quality of life in multiple sclerosis: effects of natalizumab
inferred← citeshttps://doi.org/10.1002/ana.21606openalex-snapshot
Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: A meta‐analytic approach
inferred← citeshttps://doi.org/10.1002/ana.22083openalex-snapshot
Considerations on discontinuing natalizumab for the treatment of multiple sclerosis
inferred← citeshttps://doi.org/10.1002/ana.22163openalex-snapshot
Natalizumab dosage suspension: Are we helping or hurting?
inferred← citeshttps://doi.org/10.1002/ana.22519openalex-snapshot
Role of ninjurin‐1 in the migration of myeloid cells to central nervous system inflammatory lesions
inferred← citeshttps://doi.org/10.1002/ana.25070openalex-snapshot
To do or not to do? plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy
inferred← citeshttps://doi.org/10.1002/biot.200500003openalex-snapshot
Macromolecular Immunosuppressants
inferred← citeshttps://doi.org/10.1002/brb3.362openalex-snapshot
An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis
inferred← citeshttps://doi.org/10.1002/brb3.671openalex-snapshot
Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuation
inferred← citeshttps://doi.org/10.1002/cyto.a.23910openalex-snapshot
Receptor occupation in the fjords
inferred← citeshttps://doi.org/10.1002/eji.200324502openalex-snapshot
An MHC anchor‐substituted analog of myelin oligodendrocyte glycoprotein 35–55 induces IFN‐γ and autoantibodies in the absence of experimental autoimmune encephalomyelitis and optic neuritis
inferred← citeshttps://doi.org/10.1002/eji.200324726openalex-snapshot
CYFIP2 is highly abundant in CD4+ cells from multiple sclerosis patients and is involved in T cell adhesion
inferred← citeshttps://doi.org/10.1002/eji.200535240openalex-snapshot
Increased antigen presenting cell‐mediated T cell activation in mice and patients without the autoimmune regulator
inferred← citeshttps://doi.org/10.1002/eji.201242684openalex-snapshot
Carbon monoxide‐treated dendritic cells decrease β1‐integrin induction on CD8+ T cells and protect from type 1 diabetes
inferred← citeshttps://doi.org/10.1002/eji.201546251openalex-snapshot
Postarrest stalling rather than crawling favors CD8 + over CD4 + T‐cell migration across the blood–brain barrier under flow in vitro
inferred← citeshttps://doi.org/10.1002/eji.201646485openalex-snapshot
Current multiple sclerosis treatments have improved our understanding of MS autoimmune pathogenesis
inferred← citeshttps://doi.org/10.1002/glia.20436openalex-snapshot
GSNO attenuates EAE disease byS‐nitrosylation‐mediated modulation of endothelial‐monocyte interactions
inferred← citeshttps://doi.org/10.1002/ibd.21304openalex-snapshot
Homing of immune cells: Role in homeostasis and intestinal inflammation
inferred← citeshttps://doi.org/10.1002/ibd.22940openalex-snapshot
Exclusive antagonism of the α4β7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates
inferred← citeshttps://doi.org/10.1002/j.1536-4801.2003.tb08148.xopenalex-snapshot
Blocking Lymphocyte Adhesion: New Treatment for Sticky Cases of Crohn Disease?
inferred← citeshttps://doi.org/10.1002/jcb.20052openalex-snapshot
Regulation of neuroinflammation: The role of CXCL10 in lymphocyte infiltration during autoimmune encephalomyelitis
inferred← citeshttps://doi.org/10.1002/jcph.1737openalex-snapshot
Modeling the Efficacy of Natalizumab in Multiple Sclerosis Patients Who Switch From Every‐4‐Week Dosing to Extended‐Interval Dosing
inferred← citeshttps://doi.org/10.1002/jcph.707openalex-snapshot
A Randomized Trial Evaluating Various Administration Routes of Natalizumab in Multiple Sclerosis
inferred← citeshttps://doi.org/10.1002/jcph.894openalex-snapshot
Population Pharmacokinetics and Target Engagement of Natalizumab in Patients With Multiple Sclerosis
inferred← citeshttps://doi.org/10.1002/jmri.22022openalex-snapshot
Quantitative MR in multi‐center clinical trials
inferred← citeshttps://doi.org/10.1002/jmri.23578openalex-snapshot
Shifting imaging targets in multiple sclerosis: From inflammation to neurodegeneration
inferred← citeshttps://doi.org/10.1002/jmri.23799openalex-snapshot
Advanced MR techniques in multicenter clinical trials
inferred← citeshttps://doi.org/10.1002/jnr.20255openalex-snapshot
α lipoic acid inhibits human T‐cell migration: Implications for multiple sclerosis
inferred← citeshttps://doi.org/10.1002/jnr.22176openalex-snapshot
γδ T cells: The overlooked T‐cell subset in demyelinating disease
inferred← citeshttps://doi.org/10.1002/jnr.23493openalex-snapshot
Remyelination in multiple sclerosis: Cellular mechanisms and novel therapeutic approaches
inferred← citeshttps://doi.org/10.1002/jps.21520openalex-snapshot
Interindividual Pharmacokinetics Variability of the α4β1 Integrin Antagonist, 4-[1-[3-Chloro-4-[N′-(2-methylphenyl) ureido]phenylacetyl]-(4S)-fluoro-(2S)-pyrrolidine-2-yl] methoxybenzoic Acid (D01-4582), in Beagles Is Associated with Albumin Genetic Polymorphisms
inferred← citeshttps://doi.org/10.1002/med.20243openalex-snapshot
Antigen‐specific blocking of CD4‐Specific immunological synapse formation using BPI and current therapies for autoimmune diseases
inferred← citeshttps://doi.org/10.1002/path.1434openalex-snapshot
Tight junctional abnormality in multiple sclerosis white matter affects all calibres of vessel and is associated with blood–brain barrier leakage and active demyelination
inferred← citeshttps://doi.org/10.1002/pauz.200500128openalex-snapshot
Makromolekulare Immunsuppressiva: Proteinogene Wirkstoffe
inferred← citeshttps://doi.org/10.1002/ueg2.12621openalex-snapshot
Initiation of vedolizumab did not provoke new‐onset spondylarthritis in patients with inflammatory bowel disease: A prospective 24‐week study with imaging assessments
inferred← citeshttps://doi.org/10.1007/164_2020_407openalex-snapshot
Brain Barriers and Multiple Sclerosis: Novel Treatment Approaches from a Brain Barriers Perspective
inferred← citeshttps://doi.org/10.1007/164_2021_550openalex-snapshot
Adverse Effects of Immunosuppression: Infections
inferred← citeshttps://doi.org/10.1007/3-540-30657-9_4openalex-snapshot
Specificity and Plasticity of Memory LymphocyteMigration
inferred← citeshttps://doi.org/10.1007/3-7643-7442-x_8openalex-snapshot
Lymphocyte migration to the brain
inferred← citeshttps://doi.org/10.1007/400_020openalex-snapshot
Regulation of Immune Cell Entry into the Central Nervous System
inferred← citeshttps://doi.org/10.1007/400_2008_13openalex-snapshot
Prospects for Antigen-Specific Tolerance Based Therapies for the Treatment of Multiple Sclerosis
inferred← citeshttps://doi.org/10.1007/7355_2013_21openalex-snapshot
Inflammation at the Blood–Brain Barrier in Multiple Sclerosis
inferred← citeshttps://doi.org/10.1007/978-0-387-36003-4_13openalex-snapshot
CD8+ T Cells in Multiple Sclerosis
inferred← citeshttps://doi.org/10.1007/978-0-387-36003-4_14openalex-snapshot
Review of Novel Immunotherapeutic Strategies for MS
inferred← citeshttps://doi.org/10.1007/978-0-387-75841-1_10openalex-snapshot
Case Study: Immunogenicity of Natalizumab
inferred← citeshttps://doi.org/10.1007/978-1-4419-5819-8_1openalex-snapshot
In Vivo Imaging of Cellular Transplants
inferred← citeshttps://doi.org/10.1007/978-1-4419-7219-4_6openalex-snapshot
Chemokines and Cytotoxic Effector Molecules in Rejection
inferred← citeshttps://doi.org/10.1007/978-1-4419-8959-8_16openalex-snapshot
Glutamate Excitotoxicity in Multiple Sclerosis
inferred← citeshttps://doi.org/10.1007/978-1-4614-2218-1_9openalex-snapshot
Effects of Current Medical Therapies on Reparative and Neuroprotective Functions in Multiple Sclerosis
inferred← citeshttps://doi.org/10.1007/978-1-4614-8313-7_10openalex-snapshot
The Blood–Brain Barrier in Neuroinflammation
inferred← citeshttps://doi.org/10.1007/978-1-4939-1393-0_33openalex-snapshot
VLA-4 Function and Prognosis in Acute Myeloid Leukemia
inferred← citeshttps://doi.org/10.1007/978-1-59745-001-0_6openalex-snapshot
The Immune System in the Pathogenesis of Vascular Proliferative Disease
inferred← citeshttps://doi.org/10.1007/978-1-59745-518-3_31openalex-snapshot
Clinical Use of Immunosuppressive Drugs to Control the Immune Response
inferred← citeshttps://doi.org/10.1007/978-1-61779-049-2_11openalex-snapshot
Neuroprotection in Miscellaneous Neurological Disorders
inferred← citeshttps://doi.org/10.1007/978-1-61779-903-7_14openalex-snapshot
Ghrelin Suppression of Autoimmune Encephalomyelitis
inferred← citeshttps://doi.org/10.1007/978-3-0348-0425-7_4openalex-snapshot
Progressive Multifocal Leukoencephalopathy
inferred← citeshttps://doi.org/10.1007/978-3-319-11077-6_1openalex-snapshot
The Evaluation, Diagnosis, and Treatment of Inflammatory Bowel Diseases over the Past 100 Years: A Brief Review
inferred← citeshttps://doi.org/10.1007/978-3-319-49215-5_35openalex-snapshot
New Non-anti-TNF-α Biological Therapies for the Treatment of Inflammatory Bowel Disease
inferred← citeshttps://doi.org/10.1007/978-3-540-29018-6_13openalex-snapshot
Multiple Sclerosis: New Immunobiologics
inferred← citeshttps://doi.org/10.1007/978-3-540-29018-6_16openalex-snapshot
Safety Aspects of Biologics: Lessons Learnt from Monoclonal Antibodies
inferred← citeshttps://doi.org/10.1007/978-3-540-73677-6_9openalex-snapshot
Remyelination-Promoting Human IgMs: Developing a Therapeutic Reagent for Demyelinating Disease
inferred← citeshttps://doi.org/10.1007/978-3-642-57441-2_14openalex-snapshot
Behandlung der multiplen Sklerose
inferred← citeshttps://doi.org/10.1007/978-3-662-06214-2_13openalex-snapshot
The Influence of Genetic Factors on Leukocyte and Endothelial Cell Adhesion Molecules
inferred← citeshttps://doi.org/10.1007/978-3-7643-7437-2_8openalex-snapshot
Current status of CCR1 antagonists in clinical trials
inferred← citeshttps://doi.org/10.1007/978-3-7643-7506-5_9openalex-snapshot
The resolution of airway inflammation in asthma and chronic obstructive pulmonary disease
inferred← citeshttps://doi.org/10.1007/978-90-481-9234-2_9openalex-snapshot
The Clinical Application of Ozonetherapy
inferred← citeshttps://doi.org/10.1007/978-94-007-4216-1_9openalex-snapshot
Fetal and Neonatal Illnesses Caused or Influenced by Maternal Transplacental IgG and/or Therapeutic Antibodies Applied During Pregnancy
inferred← citeshttps://doi.org/10.1007/bf03206612openalex-snapshot
Biomarkers and surrogate outcomes in neurodegenerative disease: Lessons from multiple sclerosis
inferred← citeshttps://doi.org/10.1007/bf03206672openalex-snapshot
Imaging of multiple sclerosis: Role in neurotherapeutics
inferred← citeshttps://doi.org/10.1007/s00109-007-0292-0openalex-snapshot
New developments in understanding and treating neuroinflammation
inferred← citeshttps://doi.org/10.1007/s00109-011-0835-2openalex-snapshot
Leukocyte integrin activation and deactivation: novel mechanisms of balancing inflammation
inferred← citeshttps://doi.org/10.1007/s00115-003-1665-4openalex-snapshot
Multiple Sklerose: potenzielle Therapieansätze und Update laufender Studien
inferred← citeshttps://doi.org/10.1007/s00115-005-1900-2openalex-snapshot
Blockade von Adhäsionsmolekülen mit Natalizumab in der Therapie der Multiplen Sklerose
inferred← citeshttps://doi.org/10.1007/s00115-006-2220-xopenalex-snapshot
Immunmodulatorische Stufentherapie der Multiplen Sklerose
inferred← citeshttps://doi.org/10.1007/s00115-007-2261-9openalex-snapshot
Multiple-Sklerose-Update zur Pathophysiologie und neuen immuntherapeutischen Ansätzen
inferred← citeshttps://doi.org/10.1007/s00115-007-2327-8openalex-snapshot
Fortschritte im Verständnis von Pathogenese und Immuntherapie der Multiplen Sklerose
inferred← citeshttps://doi.org/10.1007/s00115-008-2521-3openalex-snapshot
Therapieentscheidungen bei Multipler Sklerose
inferred← citeshttps://doi.org/10.1007/s00115-013-3814-8openalex-snapshot
Alemtuzumab bei schubförmig-remittierender multipler Sklerose
inferred← citeshttps://doi.org/10.1007/s00115-020-00959-0openalex-snapshot
Kopfschmerzen bei Multipler Sklerose
inferred← citeshttps://doi.org/10.1007/s00415-004-0332-4openalex-snapshot
Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis
inferred← citeshttps://doi.org/10.1007/s00415-004-0348-9openalex-snapshot
The role of oxidative stress in the pathogenesis of multiple sclerosis: The need for effective antioxidant therapy
inferred← citeshttps://doi.org/10.1007/s00415-004-0537-6openalex-snapshot
Escalating immunotherapy of multiple sclerosis
inferred← citeshttps://doi.org/10.1007/s00415-004-1505-xopenalex-snapshot
Optimising MS disease-modifying therapies: antibodies in perspective
inferred← citeshttps://doi.org/10.1007/s00415-004-1509-6openalex-snapshot
Alternatives to current disease-modifying treatment in MS: what do we need and what can we expect in the future?
inferred← citeshttps://doi.org/10.1007/s00415-006-0356-zopenalex-snapshot
A study of subtle blood brain barrier disruption in a placebo-controlled trial of natalizumab in relapsing remitting multiple sclerosis
inferred← citeshttps://doi.org/10.1007/s00415-006-5003-1openalex-snapshot
Basic principles of intravenous immunoglobulin (IVIg) treatment
inferred← citeshttps://doi.org/10.1007/s00415-006-5015-xopenalex-snapshot
Socio-economic aspects of neuroimmunological diseases
inferred← citeshttps://doi.org/10.1007/s00415-007-0684-7openalex-snapshot
Multiple sclerosis therapy: An update on recently finished trials
inferred← citeshttps://doi.org/10.1007/s00415-008-0061-1openalex-snapshot
Basic and escalating immunomodulatory treatments in multiple sclerosis: Current therapeutic recommendations
inferred← citeshttps://doi.org/10.1007/s00415-008-6006-xopenalex-snapshot
Monoclonal antibodies in the therapy of multiple sclerosis
inferred← citeshttps://doi.org/10.1007/s00415-008-6011-0openalex-snapshot
α4-Integrin antagonism with natalizumab
inferred← citeshttps://doi.org/10.1007/s00415-009-0093-1openalex-snapshot
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL
inferred← citeshttps://doi.org/10.1007/s00415-011-6019-8openalex-snapshot
Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: a prospective, 6-month observational study
inferred← citeshttps://doi.org/10.1007/s00415-011-6021-1openalex-snapshot
Improving power to detect disease progression in multiple sclerosis through alternative analysis strategies
inferred← citeshttps://doi.org/10.1007/s00415-012-6414-9openalex-snapshot
Natalizumab treatment of multiple sclerosis in Spain: results of an extensive observational study
inferred← citeshttps://doi.org/10.1007/s00415-012-6656-6openalex-snapshot
Future MS care: a consensus statement of the MS in the 21st Century Steering Group
inferred← citeshttps://doi.org/10.1007/s00415-012-6788-8openalex-snapshot
Multiple sclerosis imaging: recent advances
inferred← citeshttps://doi.org/10.1007/s00415-012-6809-7openalex-snapshot
Clinical effects of natalizumab on multiple sclerosis appear early in treatment course
inferred← citeshttps://doi.org/10.1007/s00415-014-7325-8openalex-snapshot
Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients
inferred← citeshttps://doi.org/10.1007/s00415-014-7558-6openalex-snapshot
Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE
inferred← citeshttps://doi.org/10.1007/s00415-016-8162-8openalex-snapshot
Relapse frequency in transitioning from natalizumab to dimethyl fumarate: assessment of risk factors
inferred← citeshttps://doi.org/10.1007/s00702-005-0409-yopenalex-snapshot
Molecular mechanisms involved in T cell migration across the blood–brain barrier
inferred← citeshttps://doi.org/10.1007/s00702-007-0699-3openalex-snapshot
Benefit of inhibiting SSAO in relapsing experimental autoimmune encephalomyelitis
inferred← citeshttps://doi.org/10.1007/s00702-012-0765-3openalex-snapshot
The role of kynurenines in the pathomechanism of amyotrophic lateral sclerosis and multiple sclerosis: therapeutic implications
inferred← citeshttps://doi.org/10.1007/s10072-006-0693-9openalex-snapshot
Is there or is there not a place for anti-interferon antibodies in the decision making of multiple sclerosis treatment optimisation?
inferred← citeshttps://doi.org/10.1007/s10072-008-0948-8openalex-snapshot
Natalizumab: a country-based surveillance program
inferred← citeshttps://doi.org/10.1007/s10072-009-0147-2openalex-snapshot
Treatment of multiple sclerosis: role of natalizumab
inferred← citeshttps://doi.org/10.1007/s10072-010-0470-7openalex-snapshot
The cohort of the multiple sclerosis center of Cagliari
inferred← citeshttps://doi.org/10.1007/s10072-015-2146-9openalex-snapshot
Headache in multiple sclerosis and autoimmune disorders
inferred← citeshttps://doi.org/10.1007/s10072-025-08198-4openalex-snapshot
Changes in circulating pro-inflammatory lymphocytes and cortical excitability with extended-interval natalizumab dosing in multiple sclerosis
inferred← citeshttps://doi.org/10.1007/s10571-004-1380-0openalex-snapshot
Pharmacological Targeting of ICAM-1 Signaling in Brain Endothelial Cells: Potential for Treating Neuroinflammation
inferred← citeshttps://doi.org/10.1007/s10875-008-9236-xopenalex-snapshot
Multiple Sclerosis and Regulatory T Cells
inferred← citeshttps://doi.org/10.1007/s10928-017-9514-4openalex-snapshot
Exposure–disease response analysis of natalizumab in subjects with multiple sclerosis
inferred← citeshttps://doi.org/10.1007/s11011-020-00648-6openalex-snapshot
A comprehensive review on the role of chemokines in the pathogenesis of multiple sclerosis
inferred← citeshttps://doi.org/10.1007/s11095-007-9389-yopenalex-snapshot
Targeted Delivery of Complexes of Biotin–PEG–Polyethylenimine and NF-κB Decoys to Brain-derived Endothelial Cells in Vitro
inferred← citeshttps://doi.org/10.1007/s11481-009-9179-xopenalex-snapshot
Neuropathogenesis of Theiler’s Murine Encephalomyelitis Virus Infection, An Animal Model for Multiple Sclerosis
inferred← citeshttps://doi.org/10.1007/s11481-012-9399-3openalex-snapshot
A Cannabigerol Quinone Alleviates Neuroinflammation in a Chronic Model of Multiple Sclerosis
inferred← citeshttps://doi.org/10.1007/s11882-023-01102-0openalex-snapshot
Multiple Sclerosis Pathogenesis and Updates in Targeted Therapeutic Approaches
inferred← citeshttps://doi.org/10.1007/s11894-015-0444-2openalex-snapshot
Next-Generation Therapeutics for IBD
inferred← citeshttps://doi.org/10.1007/s11910-008-0065-3openalex-snapshot
Monoclonal antibody treatments for multiple sclerosis
inferred← citeshttps://doi.org/10.1007/s11910-013-0390-zopenalex-snapshot
Monoclonal Antibodies as Disease Modifying Therapy in Multiple Sclerosis
inferred← citeshttps://doi.org/10.1007/s11910-013-0398-4openalex-snapshot
Stress in Multiple Sclerosis: Review of New Developments and Future Directions
inferred← citeshttps://doi.org/10.1007/s11910-014-0484-2openalex-snapshot
Inflammation and Immune System Activation After Traumatic Brain Injury
inferred← citeshttps://doi.org/10.1007/s11940-009-0025-5openalex-snapshot
Monoclonal antibody treatments for multiple sclerosis
inferred← citeshttps://doi.org/10.1007/s12016-014-8451-xopenalex-snapshot
Gene Therapy for Autoimmune Disease
inferred← citeshttps://doi.org/10.1007/s12035-022-02737-2openalex-snapshot
Translocator Protein Ligand PIGA1138 Reduces Disease Symptoms and Severity in Experimental Autoimmune Encephalomyelitis Model of Primary Progressive Multiple Sclerosis
inferred← citeshttps://doi.org/10.1007/s12094-011-0706-xopenalex-snapshot
Mesenchymal niches of bone marrow in cancer
inferred← citeshttps://doi.org/10.1007/s12325-021-01722-wopenalex-snapshot
Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
inferred← citeshttps://doi.org/10.1007/s13311-012-0171-4openalex-snapshot
Natalizumab Therapy for Multiple Sclerosis
inferred← citeshttps://doi.org/10.1007/s13311-017-0568-1openalex-snapshot
Bringing the HEET: The Argument for High-Efficacy Early Treatment for Pediatric-Onset Multiple Sclerosis
inferred← citeshttps://doi.org/10.1007/s13365-011-0027-4openalex-snapshot
Natalizumab and HSV meningitis
inferred← citeshttps://doi.org/10.1007/s13365-013-0222-6openalex-snapshot
Immune surveillance and response to JC virus infection and PML
inferred← citeshttps://doi.org/10.1007/s13365-023-01164-wopenalex-snapshot
Revisiting JC virus and progressive multifocal leukoencephalopathy
inferred← citeshttps://doi.org/10.1007/s15005-012-0125-8openalex-snapshot
Günstiger Einfluss auf die MRT-Aktivität nur in hoher Dosierung
inferred← citeshttps://doi.org/10.1007/s15005-014-1111-0openalex-snapshot
Antisense-Oligonukleotid reduziert Aktivität
showing the first 200 of 1205 · page through all 1205
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.